Document is current

Article History

Received: 8 March 2025

Accepted: 21 April 2025

First Online: 1 May 2025

Declarations

:

: This study was conducted in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable ethical and regulatory requirements. The study protocol was approved by independent review boards at each participating site. Safety data were periodically reviewed by a Safety Review Committee comprised of study investigators and a medical representative of the sponsor.

: All patients provided written informed consent prior to enrollment.

: Not applicable.

: Roger B Cohen has received consulting fees from Cantargia AB, Actuate and Ono, and AstraZeneca, and institutional funding from Cantargia AB, AstraZeneca, Chugai, Iconovir, Janux, and Sensei.Antonio Jimeno reports consulting for Bluedot Bio and Purple Biotech, NIH support from NCI R01 CA149456, R01DE024371, and P50 CA261605. His institution has contracts with Cantargia AB, DebioPharm, Iovance, Khar Biopharma, Merck, Moderna, Pfizer, Sanofi, and SQZ for trials where he is the local principal investigator. Lova Sun has received institutional funding from Blueprint, Seagen, IO Biotech, Erasca, Immunocore, and Abbvie, and has received honoraria/been on advisory boards for GenMab, Seagen, Bayer, Medscape, Sanofi Genzyme, and Regeneron. Marie Wallén Öhman is an employee of Cantargia AB and holds stock in Cantargia. Camilla Rydberg Millrud is an employee of Cantargia AB and holds stock in Cantargia. Annika Sanfridson is an employee of Cantargia AB and holds stock in Cantargia. Ignacio Garcia-Ribas was an employee of Cantargia AB at the time of the study, is currently a paid consultant, and holds stock in Cantargia. Jennifer Hreno has nothing to declare.